Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex; Ono Pharmaceutical
  • Developer AIO Studien gGmbH; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Eli Lilly; Emory University; Grupo Espanol Multidisciplinar de Melanoma; Incyte Corporation; Intergroupe Francophone de Cancerologie Thoracique; Janssen Biotech; Janssen Research & Development; Massachusetts General Hospital; Medarex; National Cancer Center (Tokyo); National Cancer Centre (Singapore); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Northwestern University; Ono Pharmaceutical; Pharmacyclics; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The University of Montreal Hospital Research Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Hodgkin's disease; Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Registered Colorectal cancer; Hepatocellular carcinoma
  • Phase III Glioblastoma; Mesothelioma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Small cell lung cancer
  • Phase II Acute myeloid leukaemia; Brain metastases; Breast cancer; Cancer; Carcinomatous meningitis; Cervical cancer; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Prostate cancer; Soft tissue sarcoma; Testicular cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Phase I/II Bladder cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Peritoneal cancer; Rectal cancer; Solid tumours
  • Phase I Biliary cancer; Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 16 Oct 2017 Preregistration for Malignant melanoma (Late-stage disease, Monotherapy, Adjuvant therapy) in USA (IV)
  • 16 Oct 2017 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals receives Breakthrough Therapy status for Malignant melanoma (Adjuvant therapy, Late-stage disease) in USA
  • 16 Oct 2017 The US FDA grants Priority Review status for nivolumab in Malignant melanoma (Late-stage disease, Adjuvant therapy, Monotherapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top